Altered MYO5B Function Underlies Microvillus Inclusion Disease: Opportunities for Intervention at a Cellular Level

Deanna M Bowman1, Izumi Kaji2, James R Goldenring3

  • 1Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.

Insights

Microvillus inclusion disease (MVID) is a severe newborn diarrhea caused by MYO5B mutations. Therapies targeting lysophosphatidic acid and Notch signaling show promise for restoring intestinal function.

Area of Science:

  • Gastroenterology
  • Cell Biology
  • Genetics

Background:

  • Microvillus inclusion disease (MVID) causes severe secretory diarrhea in newborns.
  • Mutations in myosin Vb (MYO5B) are linked to MVID pathology.
  • MYO5B dysfunction disrupts apical trafficking in intestinal enterocytes.

Purpose of the Study:

  • To understand the molecular mechanisms underlying MVID.
  • To identify potential therapeutic targets for MVID and congenital diarrheal disorders.
  • To investigate the role of MYO5B in enterocyte function and differentiation.

Main Methods:

  • Analysis of patient tissues, cell lines, and animal models (mice, pigs).
  • Investigation of apical trafficking pathways and endocytosis.
  • Studies on Wnt/Notch signaling pathways in enterocyte maturation.

Main Results:

  • Loss of MYO5B leads to reduced apical sodium and water transporters, causing diarrhea.
  • MYO5B loss induces microvillus inclusions via bulk endocytosis.
  • Lysophosphatidic acid (LPA) partially restores transporters; Notch inhibition improves cell differentiation.

Conclusions:

  • Therapeutic strategies involving LPA receptor activation and Notch inhibition can bypass MYO5B loss effects.
  • These approaches may restore enterocyte function and treat MVID and similar conditions.
  • Targeting these pathways offers hope for ameliorating life-threatening congenital diarrhea.